← All companies
MRK
Merck & Co., Inc. · Health Care
8 quarters · 65 figures · latest Q3 FY2026 filed 2026-10-29 →
Compared
6 of 8 · select any line below to add or remove it ·
Sales
$18.09bn+4.7% Y/YQ3 FY2026
GAAP net income
$5.07bn−12.4% Y/YQ3 FY2026
GAAP EPS
$2.04−12.1% Y/YQ3 FY2026
Gross margin
72.9%−6.2% Y/YQ3 FY2026
Cost of sales
$4.89bn+26.9% Y/YQ3 FY2026
Non-GAAP Cost of sales
$3.36bn+7.4% Y/YQ3 FY2026
Reported figures
Click any line for its full history. Each figure links to the filing it was read from.
Income statement
24 lines
| Line | Trend | Q4 FY2025 | Q1 FY2026 | Q2 FY2026 | Q3 FY2026 | Y/Y | Q/Q |
|---|---|---|---|---|---|---|---|
| Cost of salescost_of_sales | $5.55bn | $4.2bn | $4.4bn | $4.89bn | +26.9% | +11.3% | |
| Non-GAAP Cost of salescost_of_sales_non_gaap | $3.32bn | $2.94bn | $3.14bn | $3.36bn | +7.4% | +6.7% | |
| Average Shares Outstanding Assuming Dilutiondiluted_shares | 2,488 | 2,472 | 2,470 | 2,478 | −0.8% | +0.3% | |
| GAAP EPSeps_diluted | $1.19 | −$1.72 | −$0.54 | $2.04 | −12.1% | +477.8% | |
| Income Tax Provisionincome_tax_provision | $458m | $709m | $654m | $492m | −48.6% | −24.8% | |
| GAAP net incomenet_income | $2.96bn | −$4.24bn | −$1.34bn | $5.07bn | −12.4% | +479.4% | |
| Non-GAAP net income that excludes certain itemsnet_income_non_gaap | $5.09bn | −$3.16bn | −$330m | $6.16bn | −4.5% | +1966.4% | |
| Other (income) expense, netother_income_expense_net | $432m | $138m | $99m | $27m | +111.3% | −72.7% | |
| Non-GAAP other (income) expense, netother_income_expense_net_non_gaap | $226m | $318m | $290m | $420m | +296.2% | +44.8% | |
| Research and developmentrd_expense | $3.89bn | $12.59bn | $9.74bn | $4.54bn | +7.2% | −53.4% | |
| Non-GAAP Research and developmentrd_expense_non_gaap | $3.99bn | $12.56bn | $9.74bn | $4.53bn | +13.4% | −53.4% | |
| Restructuring costsrestructuring_costs | $213m | $195m | $151m | $184m | +291.5% | +21.9% | |
| Selling, general and administrativesga_expense | $2.9bn | $2.7bn | $2.9bn | $2.89bn | +9.6% | −0.6% | |
| Non-GAAP Selling, general and administrativesga_expense_non_gaap | $2.85bn | $2.67bn | $2.89bn | $2.86bn | +10.1% | −0.9% | |
| Salestotal_revenue | $16.4bn | $16.29bn | $16.61bn | $18.09bn | +4.7% | +8.9% | |
| Non-GAAP EPS that excludes certain itemseps_non_gaap | $2.04 | — | −$0.13 | $2.49 | −3.5% | +2015.4% | |
| Income Before Taxesincome_before_taxes | $3.42bn | — | — | $5.56bn | −17.6% | — | |
| Net (Loss) Incomenet_income_total | $2.96bn | — | −$1.34bn | — | −130.2% | — | |
| (Loss) Income Before Taxespretax_income | — | −$3.53bn | −$683m | — | −113.7% | +80.7% | |
| Non-GAAP EPS that excludes certain itemseps_diluted_non_gaap | — | −$1.28 | — | — | −157.7% | — | |
| Net Income (Loss)net_income_including_nci | — | — | — | $5.07bn | −12.4% | — | |
| Non-GAAP Income Before Taxesincome_before_taxes_non_gaap | — | — | — | — | $6.91bn | — | — |
| Non-GAAP income tax provisionincome_tax_provision_non_gaap | — | — | — | $882m | — | — | — |
| Non-GAAP pretax incomepretax_income_non_gaap | — | — | — | $550m | — | — | — |
Segments
33 lines
| Line | Trend | Q4 FY2025 | Q1 FY2026 | Q2 FY2026 | Q3 FY2026 | Y/Y | Q/Q |
|---|---|---|---|---|---|---|---|
| Animal Healthanimal_health_sales | $1.51bn | $1.79bn | $1.78bn | $1.68bn | +3.8% | −5.6% | |
| BRAVECTO line of productsbravecto_sales | $222m | $379m | $359m | $264m | +0.8% | −26.5% | |
| BRIDIONbridion_sales | $499m | $472m | $497m | $144m | −67.2% | −71.0% | |
| CAPVAXIVEcapvaxive_sales | $279m | $142m | $184m | $263m | +7.8% | +42.9% | |
| Companion Animalcompanion_animal_sales | $518m | $727m | $734m | $628m | +6.1% | −14.4% | |
| GARDASIL/GARDASIL 9gardasil_sales | $1.03bn | $1.07bn | $1.17bn | $2bn | +14.1% | +70.7% | |
| JANUVIA/JANUMETjanuvia_janumet_sales | $501m | $574m | $429m | $380m | −39.1% | −11.4% | |
| Keytrudakeytruda_sales | $8.37bn | $7.91bn | $7.9bn | $7.77bn | −4.6% | −1.7% | |
| Lenvimalenvima_alliance_revenue | $272m | $256m | $283m | $287m | +11.2% | +1.4% | |
| Livestocklivestock_sales | $987m | $1.06bn | $1.04bn | $1.05bn | +2.4% | +0.7% | |
| Lynparzalynparza_alliance_revenue | $389m | $341m | $365m | $352m | −7.1% | −3.6% | |
| Other Revenuesother_revenues | $52m | $146m | $72m | $141m | +182.0% | +95.8% | |
| Pharmaceuticalpharmaceutical_sales | $14.84bn | $14.35bn | $14.76bn | $16.27bn | +4.2% | +10.2% | |
| PREVYMISprevymis_sales | $275m | $272m | $295m | $347m | +30.5% | +17.6% | |
| PROQUAD, M-M-R II and VARIVAXproquad_mmr_varivax_sales | $619m | $538m | $592m | $730m | +6.7% | +23.3% | |
| Vaxneuvancevaxneuvance_sales | $140m | $202m | $148m | $195m | −13.7% | +31.8% | |
| WELIREGwelireg_sales | $220m | $199m | $271m | $307m | +56.6% | +13.3% | |
| WINREVAIRwinrevair_sales | $467m | $525m | $588m | $694m | +92.8% | +18.0% | |
| Alliance Revenue – Reblozylreblozyl_alliance_revenue | $164m | $148m | — | $177m | +30.1% | — | |
| Keytruda Qlexkeytruda_qlex_sales | — | $128m | $463m | $830m | +16500.0% | +79.3% | |
| OHTUVAYREohtuvayre_sales | $178m | $131m | $204m | $184m | — | −9.8% | |
| Adempasadempas_sales | — | — | — | $78m | −4.9% | — | |
| Alliance Revenue - Adempas/Verquvoadempas_verquvo_alliance_revenue | — | — | — | $118m | +5.4% | — | |
| Delstrigodelstrigo_sales | — | — | — | $67m | −13.0% | — | |
| Dificiddificid_sales | — | — | — | $14m | −67.4% | — | |
| ENFLONSIAenflonsia_sales | — | — | — | $187m | +136.7% | — | |
| Isentress/Isentress HDisentress_sales | — | — | — | $52m | −36.6% | — | |
| Janumetjanumet_sales | — | — | — | $194m | −20.2% | — | |
| Januviajanuvia_sales | — | — | — | $186m | −51.3% | — | |
| Other Pharmaceuticalother_pharmaceutical_sales | — | — | — | $793m | −21.0% | — | |
| Total Vaccines salestotal_vaccines_sales | — | — | $2.36bn | — | −0.4% | — | |
| Total Vaccines salesvaccines_sales | — | $2.31bn | — | — | −11.2% | — | |
| Zerbaxazerbaxa_sales | — | — | — | $90m | +11.1% | — |
Operating
4 lines
| Line | Trend | Q4 FY2025 | Q1 FY2026 | Q2 FY2026 | Q3 FY2026 | Y/Y | Q/Q |
|---|---|---|---|---|---|---|---|
| KEYTRUDA/ KEYTRUDA QLEXkeytruda_total_sales | — | $8.03bn | $8.37bn | $8.6bn | +5.6% | +2.8% | |
| LAGEVRIOlagevrio_sales | — | $28m | $5m | $17m | −87.7% | +240.0% | |
| Koselugo alliance revenuekoselugo_alliance_revenue | — | $161m | — | $13m | −93.9% | — | |
| RotaTeqrotateq_sales | — | $206m | — | $196m | −3.9% | — |
Margins
4 lines
| Line | Trend | Q4 FY2025 | Q1 FY2026 | Q2 FY2026 | Q3 FY2026 | Y/Y | Q/Q |
|---|---|---|---|---|---|---|---|
| Effective Income Tax Rateeffective_tax_rate | 13.4% | −20.1% | −95.9% | 8.9% | −37.3% | +109.3% | |
| Gross margingross_margin | 66.2% | 74.2% | 73.5% | 72.9% | −6.2% | −0.8% | |
| Non-GAAP gross margingross_margin_non_gaap | 79.7% | 81.9% | 81.1% | 81.4% | −0.6% | +0.4% | |
| Non-GAAP effective income tax rateeffective_tax_rate_non_gaap | 15.4% | −43.5% | 160.3% | 10.9% | — | −93.2% |
Guided vs delivered
What the company told the market to expect, against what it then reported. Its own guidance is the only benchmark here — no analyst estimates appear anywhere on this site.
Data from company filings. Not investment advice.